Top May Speculative Stock
3874 views
Rate Now: 1 2 3 4

average rating: 0.00 / 0 ratings
Created by RocketStocks
DESCRIPTION:

Date updated:05-22-2009

As the market and economy bottom, investors have recently turned to the most beaten down and speculative stocks imaginable in hopes of outsized profits.
The theory here is that the marginal improvement in the economy will in total have a larger affect for the smaller more beaten down companies, then say the large more globally diversified companies going forward.

symbol name last price % change open
  • +
  • BITI
    Bio-imaging Techn
  • $3.65
  • 0.00%
  • $N/A

BioImaging Technologies is the leading Contract Research Organization (CRO) focused on providing medical imaging services for clinical trials. BITI designs and manages medical imaging services, as well as evaluating the effectiveness of potential drugs and medical devices. BioImaging Technologies focuses on phase II, III and IV of the clinical trial, with north of 75% of the firm’s total revenue coming from phase III trials. Nowadays everyone wants to speculate on the next hot biotech stock like Dendreon (DNDN), BioImaging is an indirect play off the whole biotech market. Frankly, the company doesn’t care if the phase II, III, and IV work as they still get paid. In their most recent quarter, BioImaging reported the following financial data: $15 million in cash ($1 per share), $0 debt, total 2008 revenues of $72.0 million dollars, gross margins of 34%, $120 million dollar backlog of sales, and insiders own 28% of the company. Insider alignment with shareholders is massively important in terms of creating shareholder wealth. Currently, BioImaging trades for just 4x earnings making it incredibly cheap.

People owning BITI also tend to own: EPZ.VMAGPHMDSSRITQNTIWOVWOLF

TheStreet.com Rating: No Rating What is this?

  • +
  • CTIC
    Cell Therapeutics
  • $1.08
  • -2.70%
  • $1.08

Shares of Cell Therapeutics are up well over 800% since the start of the year, as rumors surrounding its only drug ‘Pixantrone’ a phase III trial drug for the treatment of non-Hodgkin’s lymphoma bubble up of a possible positive FDA ruling shortly. However, rumors are just that rumors and should be taken with a total grain of salt when it comes to money losing biotech stocks. Looking back on the history of Cell Therapeutics, one seriously has to question the competence of its current management. Shares of CTIC peaked roughly in October 2000 at $2,900 per share---where then it was trading in the $350 per share range by late 2004 and is now trading in the $1 range. The company has blown over $1.2 billion dollars since the late 1990s and hardly has much to show in terms of commercial or even experimental drugs on the market. In fact, given CTIC has about $150 million dollars in debt due this year management was forced to offer a toxic conversion to its debt holders, where debt holders would receive common equity in return for stock. This debt to equity conversion almost always is toxic to current shareholders no matter what the industry. Recently Cell Therapeutics announced that ‘Pixantrone’ is now available on a named-patient basis in Europe.

People owning CTIC also tend to own: BEAVCORVLOWFRAKAMCSCOINTC

TheStreet.com Rating: E+ What is this?

  • +
  • PCX
    Patriot Coal Corp
  • $13.45
  • 0.00%
  • $N/A

No Analysis added

People owning PCX also tend to own: ACHAMZNBRKBBTUCHLCMDELL

TheStreet.com Rating: D- What is this?

  • +
  • DNDN
    Dendreon Corporat
  • $28.01
  • -0.14%
  • $28.51

No Analysis added

People owning DNDN also tend to own: GLWUNHACASAHMATBAUYBRLC

TheStreet.com Rating: D- What is this?

  • +
  • PQ
    Petroquest Energy
  • $5.84
  • -1.02%
  • $5.86

No Analysis added

People owning PQ also tend to own: DGOOGHALMSFTSHLDTASRADELQ.PK

TheStreet.com Rating: D What is this?

Portfolio not tracked!

Comments not available

ADD YOUR COMMENTS:

Rocket Stocks for the Week

By Jonas Elmerraji Posted on Nov. 23, 2009 As well as broad-based indexes have performed in the last few months, Stockpickr's weekly Rocket Stocks list has managed to d...

11.23.09 | 10:34 AM
Cramer's Take on Headline Stocks...

Not a Stockpickr member? Join the community today -- for free.Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about...

11.20.09 | 11:48 AM
Jim Cramer's Portfolios of the Week

By Roberto Pedone Posted on Nov. 20, 2009 According to Jim Cramer, options expiration is driving the current market selloff. He pointed out that the only stocks that we...

11.20.09 | 08:09 AM
'Fast Money' Portfolios of the Week

By Roberto Pedone Posted on Nov. 19, 2009 According to CNBC’s “Fast Money” traders, the stock market is showing no signs of stopping its current bull run. Joe Ter...

11.19.09 | 11:13 AM
more articles
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZA
48 years old, IN debt, college w...
11.21.09 | 07:51 AM From author schmls
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
more forums
Q. In updating the professional por...
11.23.09 | 16:46 PM Asked by Stockpickr Staff #2

A. well, lets put it this way; i think gold
is headed for a top (dont konw how
major, but probably significant) and im
long

today 's lists
Analyst Upgrades

Analyst Upgrades or Estimate Increases for Nov. 23, 2009. Read more here. more

Stocks With Unusual Option Activity

Unusually active options can often indicate that a major event in a stock is about to take place, or that unsophisticated investors (using options in lieu of leverage) are ... more

Dogs of the Dow

Here are the 10 stocks in the Dow Jones Industrial Average stocks with the highest yields as of the market close on June 2, 2009. more